drug
ERLEADA
updated 6mo agoby Janssen Biotech Inc
community read0 votes
🐶 often sniffed alongside
top 4all catalysts(0)
nothing on the calendar yet
Trials studying ERLEADA
- phase3A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
- phase1A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
- phase1A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer
- phase2Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
- phase2Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
- phase2Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
- phase2Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
- phase3An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
News(5)
- ESMO: J&J exec says RIPTAC readout is ‘best data we’ve ever seen’ for a prostate cancer drugA year after paying over $3 billion for Halda Therapeutics, Johnson & Johnson has unveiled the first data from its shiny new RIPTAC pipeline it believes could sustain its leading role in prostate c…fiercebiotech · 25d ago
- Kairos seizes moment to push prostate cancer prospect into earlier settingKairos Pharma is moving prostate cancer prospect ENV-105 into an earlier line of treatment in response to midphase survival data.fiercebiotech · 1mo ago
- J&J dips despite upbeat outlook; AstraZeneca, Spero cut China dealsJ&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.biopharma_dive · 4mo ago
- #ASCO26: Erleada succeeds in early-stage prostate cancer study, but questions remainCHICAGO — As part of a hormone therapy regimen for prostate cancer, J&J’s Erleada cut the risk of metastasis or death by 20% when given around surgery, researchers reported Sunday. Treatment with t…endpoints · 5mo ago
- GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.onclive · 6mo ago
Data sources
last refreshed 6h ago
Found something off?
comments(0)
5-min edit window · permanent after that